Search

Your search keyword '"Farinati, F."' showing total 1,443 results

Search Constraints

Start Over You searched for: Author "Farinati, F." Remove constraint Author: "Farinati, F."
1,443 results on '"Farinati, F."'

Search Results

2. Distinguishing features of autoimmune gastritis depending on previous H. pylori infection or positivity to anti-parietal cell antibodies: Results from the Autoimmune gastRitis Italian netwOrk Study grOup (ARIOSO)

3. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept

5. Predictors of extrahepatic progression in patients with hepatocellular carcinoma receiving transarterial chemoembolization

6. Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery

10. Preoperative predictors of recurrence beyond Milan criteria in hepatocellular carcinoma patients treated with frontline liver resection

12. Lack of substantial improvements in the landscape of alcohol-related hepatocellular carcinoma in the last 15 years: The need to improve cancer prevention and surveillance

13. Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications

14. Pattern of macrovascular invasion in hepatocellular carcinoma

15. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study

17. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

21. Correction to: Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson’s disease on levodopa/carbidopa intestinal gel infusion (Journal of Neurology, (2022), 269, 10, (5606-5614), 10.1007/s00415-022-11269-7)

22. Cysteine and Serine Proteases in Duodenal Ulcer

24. Zinc and Digestive Diseases

28. Years of life that could be saved from prevention of hepatocellular carcinoma

29. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome

34. OC.08.5 EFFECTIVENESS OF EMPIRICAL SECOND-LINE H. PYLORI ERADICATION THERAPY IN ITALY: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

36. OC.08.4 ANTIBIOTIC RESISTANCE TRENDS OF ITALIAN H. PYLORI NAÏVE PATIENTS BETWEEN 2013-2020: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

40. AF.24 CHARACTERISTICS OF EMPIRICAL FIRST- AND SECOND-LINE TREATMENT BETWEEN 2013-2020: ITALIAN DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

42. OC.08.2 EFFECTIVENESS OF EMPIRICAL FIRST-LINE H. PYLORI ERADICATION THERAPY IN ITALY: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

43. Pattern of macrovascular invasion in hepatocellular carcinoma

44. The changing scenario of hepatocellular carcinoma in Italy: an update

45. Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter

46. Identification of clinical phenotypes and related survival in patients with large hccs

47. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study

48. Monofocal hepatocellular carcinoma: How much does size matter?

49. Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients

Catalog

Books, media, physical & digital resources